Literature DB >> 25304213

Novel nucleophiles enhance the human serum paraoxonase 1 (PON1)-mediated detoxication of organophosphates.

Janice E Chambers1, Howard W Chambers2, Edward C Meek2, Kristen E Funck2, Manikanthan H Bhavaraju2, Steven R Gwaltney2, Ronald B Pringle2.   

Abstract

Paraoxonase 1 (PON1) is a calcium-dependent hydrolase associated with serum high-density lipoprotein particles. PON1 hydrolyzes some organophosphates (OPs), including some nerve agents, through nucleophilic attack of hydroxide ion (from water) in the active site. Most OPs are hydrolyzed inefficiently. This project seeks to identify nucleophiles that can enhance PON1-mediated OP degradation. A series of novel nucleophiles, substituted phenoxyalkyl pyridinium oximes, has been synthesized which enhance the degradation of surrogates of sarin (nitrophenyl isopropyl methylphosphonate; NIMP) and VX (nitrophenyl ethyl methylphosphonate; NEMP). Two types of in vitro assays have been conducted, a direct assay using millimolar concentrations of substrate with direct spectrophotometric quantitation of a hydrolysis product (4-nitrophenol) and an indirect assay using submicromolar concentrations of substrate with quantitation by the level of inhibition of an exogenous source of acetylcholinesterase from non-hydrolyzed substrate. Neither NIMP nor NEMP is hydrolyzed effectively by PON1 if one of these novel oximes is absent. However, in the presence of eight novel oximes, PON1-mediated degradation of both surrogates occurs. Computational modeling has created a model of PON1 embedded in phospholipid and has indicated general agreement of the binding enthalpies with the relative efficacy as PON1 enhancers. PON1 enhancement of degradation of OPs could be a unique and unprecedented mechanism of antidotal action.
© The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology.All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  PON1; VX surrogate; paraoxon; paraoxonase 1; sarin surrogate

Mesh:

Substances:

Year:  2014        PMID: 25304213     DOI: 10.1093/toxsci/kfu205

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  6 in total

Review 1.  Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.

Authors:  A R Satvik Iyengar; Abhay H Pande
Journal:  Protein J       Date:  2016-12       Impact factor: 2.371

Review 2.  Novel approaches to mitigating parathion toxicity: targeting cytochrome P450-mediated metabolism with menadione.

Authors:  Yi-Hua Jan; Jason R Richardson; Angela A Baker; Vladimir Mishin; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Ann N Y Acad Sci       Date:  2016-07-21       Impact factor: 5.691

Review 3.  Central neuroprotection demonstrated by novel oxime countermeasures to nerve agent surrogates.

Authors:  Janice E Chambers; Edward C Meek
Journal:  Ann N Y Acad Sci       Date:  2020-04-21       Impact factor: 6.499

4.  Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells.

Authors:  Mark Borris D Aldonza; Yeon Sung Son; Hye-Jin Sung; Jung Mo Ahn; Young-Jin Choi; Yong-In Kim; Sukki Cho; Je-Yoel Cho
Journal:  Oncotarget       Date:  2017-06-27

5.  Novel pyridinium oximes enhance 24-h survivability against a lethal dose of nerve agent surrogate in adult female rats.

Authors:  Jason M Garcia; Edward C Meek; Janice E Chambers
Journal:  Toxicology       Date:  2020-11-04       Impact factor: 4.221

6.  Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study.

Authors:  Laura Xicota; Farid Ichou; François-Xavier Lejeune; Benoit Colsch; Arthur Tenenhaus; Inka Leroy; Gaëlle Fontaine; Marie Lhomme; Hugo Bertin; Marie-Odile Habert; Stéphane Epelbaum; Bruno Dubois; Fanny Mochel; Marie-Claude Potier
Journal:  EBioMedicine       Date:  2019-09-03       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.